Correlation of cardiac 123I-MIBG imaging with conventional markers of the heart failure

[1] Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22-31.Search in Google Scholar

[2] Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jaques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J NuclMed 1987;28:1620-4.Search in Google Scholar

[3] Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 1984;311:819-23.10.1056/NEJM198409273111303Search in Google Scholar

[4] Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.10.1016/0735-1097(92)90167-LSearch in Google Scholar

[5] Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.10.1007/s00259-007-0639-318043919Search in Google Scholar

[6] Jacobson AF, Senior R, Cerqueira MD,Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 metaiodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.10.1016/j.jacc.2010.01.01420188504Search in Google Scholar

[7] Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiacmetaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.Search in Google Scholar

[8] Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois- Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J NuclMed 1999;40:917-23.Search in Google Scholar

[9] Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2769-77.10.1016/j.jacc.2009.12.06620538172Search in Google Scholar

[10] Paul M,Wichter T, Kies P, Gerss J,Wollmann C, Rahbar K, et al. Cardiac sympathetic dysfunction in genotyped patients with arrhythmogenic right ventricular cardiomyopathy and risk of recurrent ventricular tachyarrhythmias. J NuclMed 2011;52:1-7.10.2967/jnumed.111.08899721908389Search in Google Scholar

[11] Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.10.1007/s00259-007-0639-3Search in Google Scholar

[12] Arimoto T, Takeishi Y, Niizeki T, Koyama Y, Okuyama H, Nozaki N, et al. Ongoing myocardial damage relates to cardiac sympathetic nervous disintegrity in patients with heart failure. Ann Nucl Med 2005;19:535-40.10.1007/BF0298504516363617Search in Google Scholar

[13] Fujimoto S, Amano H, Inoue A, Ishida S, Yamashina S, Yamashina H, et al. Usefulness of 123Imetaiodobenzylguanidine myocardial scintigraphy in the prediction of cardiac events in patients with cardiomyopathy showing stabilization of symptoms or preserved cardiac function. Ann Nucl Med 2004;18:591-8.10.1007/BF0298458115586633Search in Google Scholar

[14] Katoh S, Shishido T, Kutsuzawa D, Arimoto T, Netsu S, Funayama A, et al. Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction. Ann Nucl Med 2010;24:679-86.10.1007/s12149-010-0409-320824398Search in Google Scholar

[15] Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J NuclMedMol Imaging 2010;37:1802-12.10.1007/s00259-010-1491-4Search in Google Scholar

[16] Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F, et al. Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol 2003;10:623-32.10.1016/S1071-3581(03)00652-4Search in Google Scholar

[17] Germano G, Kavanagh PB, Chen J, Waechter P, Su HT, Kiat H, et al. Operator-less processing of myocardial perfusion SPECT studies. J NuclMed 1995;36:2127-32.Search in Google Scholar

[18] Bax JJ, Boogers M, Henneman MM. Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients? Eur J Nucl Med Mol Imaging 2008;35:532-4.10.1007/s00259-008-0722-4227577518210105Search in Google Scholar

[19] Higuchi K, Toyama T, Tada H, Naito S, Ohshima S, Kurabayashi M. Usefulness of biventricular pacing to improve cardiac symptoms, exercise capacity and sympathetic nerve activity in patients with moderate to severe chronic heart failure. Circ J 2006;70:703-9.10.1253/circj.70.70316723791Search in Google Scholar